Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
D000328:Adult; D000368:Aged; D006585:Altretamine / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008936:Mitolactol / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D013997:Time Factors; D014227:Triazines / Q000627:therapeutic use*
D014227:Triazines; D008936:Mitolactol; D006585:Altretamine